Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Iadademstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ORYZON To Participate In Upcoming Events In May And June
    ORYZON To Participate In Upcoming Events In May And June

    29 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/29/3283692/0/en/oryzon-to-participate-in-upcoming-events-in-may-and-june.html

    GLOBENEWSWIRE
    29 Apr 2026
    Share Share
    ORYZON Secures U.S. Patent For Iadademstat And Venetoclax
    ORYZON Secures U.S. Patent For Iadademstat And Venetoclax

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260315/0/en/ORYZON-Announces-U-S-Patent-Grant-Covering-Iadademstat-Combinations-with-Venetoclax.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    ORYZON Secures Mexico Patent For Iadademstat Combo
    ORYZON Secures Mexico Patent For Iadademstat Combo

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254559/0/en/ORYZON-Expands-Patent-Protection-for-Iadademstat-with-Grant-Decision-in-Mexico-Covering-Combinations-with-PD-1-PD-L1-Inhibitors.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    ORYZON Initiates Phase Ib Study Of Iadademstat In Extensive
    ORYZON Initiates Phase Ib Study Of Iadademstat In Extensive

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234486/0/en/ORYZON-Announces-First-Patient-Dosed-in-an-Investigator-Initiated-Phase-Ib-Study-of-Iadademstat-in-Extensive-Stage-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Oryzon Presents Iadademstat AML Data at 67th ASH Annual Meeting
    Oryzon Presents Iadademstat AML Data at 67th ASH Annual Meeting

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202300/0/en/ORYZON-Presents-Data-for-Iadademstat-Combinations-in-AML-at-the-American-Society-of-Hematology-ASH-67th-Annual-Meeting.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    ORYZON Reveals Positive Iadademstat Clinical Data At ASH-2025
    ORYZON Reveals Positive Iadademstat Clinical Data At ASH-2025

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180259/0/en/ORYZON-Announces-Positive-Clinical-Data-of-Iadademstat-at-ASH-2025.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.